Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolic bone disease in patients with liver disease.

Literature DB >> 12530951

Metabolic bone disease in patients with liver disease.

Abstract

The coexistence of liver disease and osteopenic bone disease has been recognized for many years and is now the subject of increasing attention. Osteoporosis has been characterized well in patients with cholestatic liver disease, but new research suggests that osteopenia and osteoporosis may also be prevalent in patients with other chronic liver diseases. Although the precise mechanism of bone loss remains unclear, advances in treatment and prevention are bringing heightened awareness to this common problem.

Entities: Disease Species

Mesh：

Year: 2003 PMID： 12530951 DOI： 10.1007/s11894-003-0012-z

Source DB: PubMed Journal: Curr Gastroenterol Rep ISSN： 1522-8037

49 in total

1. Guidelines on the management of osteoporosis associated with chronic liver disease.

Authors: Jane D Collier; M Ninkovic; J E Compston
Journal: Gut Date: 2002-02 Impact factor: 23.059

2. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

Authors: A Floreani; F Zappala; W Fries; R Naccarato; M Plebani; A D'Angelo; M Chiaramonte
Journal: J Clin Gastroenterol Date: 1997-06 Impact factor: 3.062

3. Bone disease in liver transplant recipients: incidence, timing, and risk factors.

Authors: M K Porayko; R H Wiesner; J E Hay; R A Krom; E R Dickson; S Beaver; L Schwerman
Journal: Transplant Proc Date: 1991-02 Impact factor: 1.066

Review 4. Skeletal response to alcohol.

Authors: R T Turner
Journal: Alcohol Clin Exp Res Date: 2000-11 Impact factor: 3.455

5. Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis.

Authors: N Hattori; H Kurahachi; K Ikekubo; T Ishihara; K Moridera; M Hino; Y Saiki; H Imura
Journal: Metabolism Date: 1992-04 Impact factor: 8.694

6. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis.

Authors: J E Hay; M Malinchoc; E R Dickson
Journal: J Hepatol Date: 2001-02 Impact factor: 25.083

7. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.

Authors: O Epstein; Y Kato; R Dick; S Sherlock
Journal: Am J Clin Nutr Date: 1982-09 Impact factor: 7.045

Metabolic bone disease in patients with liver disease.

1. Guidelines on the management of osteoporosis associated with chronic liver disease.

2. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

3. Bone disease in liver transplant recipients: incidence, timing, and risk factors.

Review 4. Skeletal response to alcohol.

5. Serum growth hormone-binding protein, insulin-like growth factor-I, and growth hormone in patients with liver cirrhosis.

6. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis.

7. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis.

8. Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.

9. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment.

10. Sodium fluoride prevents bone loss in primary biliary cirrhosis.

1. Renal and Gastrointestinal Considerations in Joint Replacement Surgery.